A surprise new name was thrown into the ring to take on Pfizer’s healthcare unit but speculation suggests that valuation is once again the sticking point, indicating that Pfizer may not be able to find anyone willing to acquire the unit this time around.
Procter & Gamble were the latest to be added to the list of suitors for the unit, and appeared as a surprise mainly because the bidding process had been deemed to be over.
Original Article: Pfizer running out of options for consumer business